C12N 2310/323
Modified ring structure
Official title: modified ring structure
C12N2310/323 (Modified ring structure) appears on 1,562 US grants and 3,185 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,562
- Published applications
- 3,185
- Assignees
- 777
- Inventors
- 3,425
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 2 | 0 |
| 2001 | 4 | 2 |
| 2002 | 2 | 4 |
| 2003 | 2 | 21 |
| 2004 | 5 | 17 |
| 2005 | 4 | 32 |
| 2006 | 4 | 23 |
| 2007 | 3 | 40 |
| 2008 | 4 | 26 |
| 2009 | 10 | 55 |
| 2010 | 25 | 56 |
| 2011 | 25 | 72 |
| 2012 | 32 | 91 |
| 2013 | 58 | 87 |
| 2014 | 58 | 138 |
| 2015 | 93 | 189 |
| 2016 | 114 | 184 |
| 2017 | 115 | 174 |
| 2018 | 131 | 191 |
| 2019 | 131 | 199 |
| 2020 | 116 | 194 |
| 2021 | 137 | 237 |
| 2022 | 119 | 248 |
| 2023 | 92 | 242 |
| 2024 | 102 | 241 |
| 2025 | 97 | 270 |
| 2026 | 76 | 152 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Compositions for delivery of antisense compounds22 Sep 2026US 12,741,989 B2Entrada Therapeutics, Inc.
- Compositions and methods for suppressing intracellular synthesis of the beta subunit of human chorionic gonadotropin1 Sep 2026US 12,721,896 B1
- Linked target capture1 Sep 2026US 12,723,277 B2Ncan Genomics, Inc.
- Antagonism as a therapy for TDP-43 proteinopathies25 Aug 2026US 12,716,065 B2University of Southern California
- Polynucleotide conjugates comprising PLN-targeting anti-transferrin receptor antibodies and method of use thereof to treat PLN-associated cardiomyopathies18 Aug 2026US 12,708,669 B2Atrium Therapeutics, Inc.
- Modified guide rnas8 Oct 2026US 2026/0308577 A1Genentech, Inc.
- Methods of treatment of chronic kidney disease8 Oct 2026US 2026/0308590 A1AstraZeneca AB
- Treatment of gpam related diseases and disorders8 Oct 2026US 2026/0308594 A1Empirico Inc.
- Antisense oligomer formulations8 Oct 2026US 2026/0308595 A1Stoke Therapeutics, Inc.
- Methods of minimising effects of smoke exposure8 Oct 2026US 2026/0308597 A1Rage Biotech Pty Ltd
Most cited
By later US patents
- Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation323US 7,696,345 B2Isis Pharmaceuticals, Inc. · 2010
- Alteration of cellular behavior by antisense modulation of mRNA processing259US 6,210,892 B1Isis Pharmaceuticals, Inc. · 2001
- Antisense modulation of BCL-X expression218US 6,172,216 B2Isis Pharmaceuticals, Inc. · 2001
- Compositions and methods for inhibiting expression of Eg5 gene215US 7,718,629 B2Alnylam Pharmaceuticals, Inc. · 2010
- Oligonucleotides with alternating segments of locked and non-locked nucleotides183US 7,687,617 B2Santaris Pharma A/S · 2010